Lilly welcomes a trade ruling against imported knockoff tirzepatide

A judge overseeing Eli Lilly's case at the U.S. International Trade Commission ruled that Customs and Border Protection should block the illegal import of knockoff tirzepatide products, the company said on December 23, 2024 ^[1]. Tirzepatide is the active ingredient in Lilly's Mounjaro and Zepbound. The ruling found that seven entities based in China, Spain, Texas, Florida, and Iowa violated federal law because their conduct was likely to deceive consumers about whether their imported "tirzepatide" products were genuine Lilly medicines, and because some falsely claimed the products had gone through clinical trials, were FDA-approved, or even contained tirzepatide when they did not ^[1].

Lilly says the order applies broadly to anyone importing illicit knockoff tirzepatide, not just the seven named parties ^[1]. Patrik Jonsson, an Eli Lilly executive vice president and president of Lilly Cardiometabolic Health and Lilly USA, said knockoff medicines or their ingredients are "often produced abroad in unregistered facilities that have never been inspected by any regulatory agency" ^[1]. He added that Lilly has intercepted illegal shipments from China labeled as tirzepatide but disguised as dog food, tea, facial masks, or hidden inside boxes of t-shirts ^[1].

The company cited specific safety findings to back up its concerns. Lilly said it continues to find knockoff tirzepatide contaminated with bacteria, high endotoxin levels, and high impurity levels ^[1]. Testing also turned up potency problems: some knockoff products contained more tirzepatide than labeled, raising overdose risk, while almost half of the knockoff samples Lilly tested had potency below the labeled amount, and some contained no tirzepatide at all ^[1]. Separately, ABC News reported testing semaglutide and tirzepatide products bought online and found some samples had none of the active ingredient while others had 250% of the advertised potency ^[1]. The Tennessee Drug Task Force reported counterfeit tirzepatide being sold directly to patients at med-spas ^[1].

Regulators outside the U.S. have raised similar alarms. Lilly said Australia banned compounded incretins entirely this year over safety concerns, and health regulators in South Africa, Brazil, and Ireland have warned patients against unapproved knockoffs ^[1]. In December 2024, the American Diabetes Association published guidance recommending patients not use compounded incretin products "due to uncertainty about their content and resulting concerns about safety, quality, and effectiveness" ^[1]. The FDA has also warned patients, including a November 2024 alert about tirzepatide products from a licensed California compounder that "used non-sterile ingredients" and "took no steps to sterilize them" ^[1].

Why it matters for patients

Most enforcement actions against fake or compounded GLP-1 drugs have targeted domestic pharmacies or compounders. This ITC ruling instead aims at the international supply chain that feeds counterfeit and knockoff tirzepatide into the U.S. market ^[1]. For patients, the practical risk is that products sold as tirzepatide, whether bought online, through unlicensed sellers, or at outlets like med-spas, may not contain the labeled ingredient at all, may contain too much or too little of it, or may be contaminated ^[1]. The FDA has warned that compounded and counterfeit products can lead to serious and potentially life-threatening adverse health consequences including infections and sepsis ^[1]. Widespread availability of a product does not mean it is safe ^[1].

What happens next

Lilly said it will continue pursuing legal action against what it calls bad actors and is calling on state and federal regulators to take further action ^[1]. The sources provided do not specify a timeline for when Customs and Border Protection enforcement under the ITC order will take effect or how it will be implemented at the border.